Phase 3 study results show dry eye therapy safe but ineffective

Results from a 24 week placebo-controlled phase 3 study recently released by OphthaliX showed that the company’s licensed drug, CF101, for the treatment of dry eye, while well-tolerated, met neither primary nor secondary efficacy endpoints, according to a company press release.The study included 237 patients with moderate-to-severe dry eye syndrome randomized to receive two oral doses of CF101, an A3 adenosine receptor agonist (0.1 mg or 1.0 mg), or a placebo, for a period of 24 weeks, the release said.

Full Story →